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Abstract
The reciprocal interaction between cancer cells and the tissue-specific stroma is
critical for primary and metastatic tumor growth progression. Prostate cancer cells
colonize preferentially bone (osteotropism), where they alter the physiological
balance between osteoblast-mediated bone formation and osteoclast-mediated
bone resorption, and elicit prevalently an osteoblastic response (osteoinduction).
The molecular cues provided by osteoblasts for the survival and growth of bone
metastatic prostate cancer cells are largely unknown. We exploited the sufficient
divergence between human and mouse RNA sequences together with redefinition
of highly species-specific gene arrays by computer-aided and experimental
exclusion of cross-hybridizing oligonucleotide probes. This strategy allowed the
dissection of the stroma (mouse) from the cancer cell (human) transcriptome in
bone metastasis xenograft models of human osteoinductive prostate cancer cells
(VCaP and C4-2B). As a result, we generated the osteoblastic bone metastasis-
associated stroma transcriptome (OB-BMST). Subtraction of genes shared by
inflammation, wound healing and desmoplastic responses, and by the tissue
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type-independent stroma responses to a variety of non-osteotropic and osteotropic
primary cancers generated a curated gene signature (‘‘Core’’ OB-BMST) putatively
representing the bone marrow/bone-specific stroma response to prostate cancer-
induced, osteoblastic bone metastasis. The expression pattern of three
representative Core OB-BMST genes (PTN, EPHA3 and FSCN1) seems to confirm
the bone specificity of this response. A robust induction of genes involved in
osteogenesis and angiogenesis dominates both the OB-BMST and Core OB-
BMST. This translates in an amplification of hematopoietic and, remarkably,
prostate epithelial stem cell niche components that may function as a self-
reinforcing bone metastatic niche providing a growth support specific for
osteoinductive prostate cancer cells. The induction of this combinatorial stem cell
niche is a novel mechanism that may also explain cancer cell osteotropism and
local interference with hematopoiesis (myelophthisis). Accordingly, these stem cell
niche components may represent innovative therapeutic targets and/or serum
biomarkers in osteoblastic bone metastasis.
Introduction
Prostate cancer (PCa) is the most common solid cancer in men in the western
world. Despite early detection and surgical treatment of the tumor, 10–20% of
PCa patients show bone metastases at diagnosis [1] and .80% of advanced PCa
patients have bone metastases at autopsy [2]. Bone metastases are the most
important cause of morbidity in these patients and, once developed, are incurable.
In primary and metastatic cancers neoplastic cells closely interact with different
cell types and the extracellular matrix (ECM) constituting the stroma
compartment. This leads to activation of the stroma and, in turn, to the secretion
of additional growth factors, matrix proteins and proteases, which further favor
cancer cell proliferation and invasion. These heterogeneous and bi-directional
interactions within the tumor tissue are fundamental for tumor growth
progression [3]. Therefore, elucidation of the mechanism(s) determining the
initiation and progression of metastatic growth is essential for the identification of
novel therapeutic targets for prevention and/or treatment of cancer metastases.
In bone metastases activation of the bone marrow/bone (BM/B) stroma by
cancer cells alters the physiological balance between osteoblast (OB)-mediated
bone formation and osteoclast (OC)-mediated bone resorption, and interferes
with hematopoiesis (myelophthisis). PCa elicits predominantly an OB response,
with a consequent increase in bone formation (osteoinduction) and generation of
osteosclerotic lesions [4]. Instead, mammary cancer (MCa) triggers preferentially
an OC reaction, resulting in exaggerated bone resorption and generation of
osteolytic lesions [5]. These opposite stromal reactions may underlie different
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growth support requirements between pro-osteolytic and osteoinductive cancer
cells.
Factors released from the bone matrix during OC-mediated bone resorption
fuel the proliferation of cancer cells, which stimulate further bone resorption,
thereby leading to a self-perpetuating, positive feedback loop. This mechanism,
known as the ‘‘Vicious Cycle’’ hypothesis of bone resorption and tumor growth in
osteolytic bone metastases is a paradigmatic example of cancer cell-stroma
interaction and has provided the rationale for interfering with the bone stroma
support by inhibition of bone resorption [6]. However, the molecular cues
provided by OBs for survival and growth of osteoinductive cancer cells have
remained largely elusive [4].
Paget’s ‘‘Seed & Soil’’ hypothesis [7] postulates that cancer cells (the ‘‘seed’’)
from the primary tumor can disseminate to various tissues, but succeed in
establishing secondary growth only in those that are permissive for their survival
and/or proliferative expansion (the ‘‘fertile soil’’) [8]. Thus, the ‘‘Seed & Soil’’
hypothesis embodies the propensity of certain cancers to metastasize to specific
tissues (tissue tropism). Paget was also the first to recognize that MCa
metastasizes almost exclusively to the axial skeleton, site of the red marrow [7].
This observation suggests that active hematopoiesis may represent the fertile soil
for seeding of cancer cells, which may therefore mimic hematopoietic stem cells
(HSCs) for homing, survival and/or expansion in the BM/B [9]. This hypothesis,
implying that the BM/B metastatic niche may match with the HSC niche, has been
experimentally validated by showing that PCa cells hijack the HSC niche(s) for
homing in the BM/B [10].
Most attempts to decipher the cancer gene signatures highlighting signaling
pathways critical for cancer progression or predicting patient outcome have been
performed by gene expression profiling in clinical samples of bulk tumor tissue.
Obviously, this strategy cannot discriminate between cancer- and stroma-derived
gene expression. Naef and Huelsken [11] have developed a method of ‘‘tissue
compartment-specific transcriptional profiling’’ (TCTP), which allows simulta-
neous analysis of gene expression specific for the cancer cell and the stromal
compartment in situ, without prior cell separation. This approach exploits
differences between human and mouse RNA sequences and selects the most
species-specific oligonucleotide probes by a computational mask. By a similar
strategy we generated the osteoblastic bone metastasis-associated stroma
transcriptome (OB-BMST) defining for the first time the global stroma response
in bone xenograft models of osteoinductive PCa cells.
Results
Osteoinductive PCa cells alter the BM/B stroma transcriptome
The strategy adopted to investigate transcriptome changes that occur specifically
in the stroma compartment of bones xenografted with human osteoinductive
prostate cancer cells is outlined in Fig. 1A.
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Fig. 1. The gene expression pattern changes in bones xenografted with osteoinductive PCa cells. A. Flow chart outlining experimental (blue) and
bioinformatics (grey) steps adopted to define a complete (OB-BMST) and a curated (‘‘Core’’ OB-BMST) stroma response signature (orange). The first two
experimental steps constitute the tissue compartment-specific transcriptional profiling (TCTP). B. Heatmap showing differentially expressed probe-sets
between xenografted (C4-2B and VCaP) and control (Ep156T, intact and sham) bones. The expression level is color-coded: low expression is represented
in blue, whereas high expression is represented in red. C. Venn diagram showing the number of overlapping and unique genes differentially expressed in
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The differentially expressed probe sets clearly separate cancer-cell xenografted
bones from control bones, as highlighted by hierarchical clustering (Fig. 1B). The
heatmap shows homogeneous clustering within the xenografts, but the
dendrogram still indicates that the C4-2B and VCaP xenografts separate in two
branches. All control samples also cluster together, suggesting that surgical
intervention and inoculation of non-tumorigenic, normal human prostate
epithelial cells (Ep156T) did not cause major modifications in gene expression.
Additionally, the heatmap indicates that in xenografts the prevalent part of genes
(64%) were up-regulated.
When compared to the sham-operated bones, 654 genes are differentially
expressed in C4-2B xenografts (false discovery rate, FDR#1E-05) and 583 genes in
VCaP xenografts (FDR#3E-05) (Fig. 1C, S1 Table). The sum of these
differentially expressed genes will be referred to as the OB-BMST.
A total of 321 genes from the OB-BMST are common to both C4-2B and VCaP
xenografts (Fig. 1C, S1 Table). The scatter plot of log2 fold change for both
xenografts shows a significant correlation (R250.96) (Fig. 1D), indicating a
complete concordance of gene regulation for both models of osteoblastic bone
metastasis. However, within the OB-BMST, 333 and 262 genes are unique for C4-
2B and VCaP, respectively. Differences in osteoinductive potential (VCaP.C4-
2B) and/or in growth kinetics (C4-2B.VCaP) may explain this partial diversity of
stroma reaction induced by the two cell lines. Nevertheless, among the top 30
most up-regulated genes 18 are shared by C4-2B and VCaP xenografts (Fig. 1E,
S1 Table), indicating that both cell lines are comparable in inducing the
predominant stroma reaction.
The OB-BMST associates with myoepithelial/myofibroblast
signature
To identify the cell type primarily responsible for the OB-BMST expression, we
compared the up-regulated genes of the OB-BMST with gene signatures
previously derived from specific stroma cell populations in mammary tumors
[12]. This analysis shows that, the OB-BMST mainly overlaps with the
myoepithelial/myofibroblast signature and, to a minor extent, with the fibroblast
and EC signatures (S1 Figure).
A fraction of the OB-BMST is not specific for the BM/B response to
osteoinductive PCa cells
The analysis of the expression of a 7-gene set of highly up-regulated OB-BMST
genes, namely periostin (Postn), asporin (Aspn), SPARC-like 1 (Sparcl1),
melanoma cell adhesion molecule (Mcam), platelet derived growth factor receptor
C4-2B (FDR51E-05) and VCaP (FDR53E-05) xenografted bones. The sum of differentially expressed genes is referred to as the OB-BMST. D. Scatter plot
showing log2 fold change of differentially expressed genes in C4-2B and VCaP xenografts. E. Top 30 up-regulated genes of the OB-BMST derived from C4-
2B (black bars) and VCaP (grey bars) xenografted bones.
doi:10.1371/journal.pone.0114530.g001
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beta (Pdgfrb), fascin homolog 1 (Fscn1) and prostate transmembrane protein,
androgen induced 1 (Pmepa1) revealed that these genes are not only induced in
the stroma of bones xenografted with C4-2B and VCaP cells (S2A Figure), but
also in orthotopic VCaP xenografts (S2B Figure) and in ectopic (S2C Figure)
xenografts of both C4-2B and VCaP cells. In addition, the expression of the 7-gene
set is induced also in bones xenografted with the pro-osteolytic PCa cell line PC-3
(S2D Figure). Furthermore, ASPN and POSTN expression is not only increased
in the stroma of bone metastatic human PCa, but also of primary PCa and of bone
metastatic human MCa (S3 Figure).
Taken together, the results above suggest that a fraction of the OB-BMST is not
specific for the BM/B response to osteoinductive PCa cells. However, the finding
that proteins encoded by genes of the OB-BMST are overexpressed also in the
stroma of human primary and bone metastatic tumors underscores the
translational value of the OB-BMST.
A fraction of the OB-BMST is specific for the BM/B response to
osteoinductive PCa cells
To identify the OB-BMST component specific to the osteoblastic bone metastases,
we subtracted from the OB-BMST stroma gene signatures derived from
inflammatory/wound healing and desmoplastic responses, and from non-
osteotropic and osteotropic cancers (Fig. 1A).
This strategy, referred to, thereafter, as ‘‘curation’’, has led to the identification
of 4 major components within the OB-BMST: 1) a component putatively specific
for the BM/B stroma response to osteoinductive PCa cells, from now on referred
to as ‘‘Core OB-BMST’’, 2) a component shared with ‘‘inflammatory/wound
healing/desmoplastic’’ response signatures, 3) a component possibly representing
a ‘‘universal’’ response to cancer cells and 4) a candidate ‘‘osteotropic’’ signature.
The Core OB-BMST, covering 72.6% of the OB-BMST, consists of 336 up-
regulated and 298 down-regulated genes. Of these, 109 and 93, respectively, are
common to both C4-2B and VCaP xenografts (Fig. 2A, S2 Table). These genes
are likely to be restricted to the BM/B stroma reaction to osteoinductive cancer
cell growth. However, the specificity of the Core OB-BMST should be considered
with caution since our subtractive strategy was limited to publicly available gene
signatures and did not consider studies concerning single gene and/or protein
expression in a variety of cancers.
The top 10 genes of the Core OB-BMST list (Fig. 2B, S2 Table) are conserved
from the top 30 most up-regulated genes of the OB-BMST (Fig. 1E, S1 Table).
Among the top 30 genes of the Core OB-BMST, 12 are common to C4-2B and
VCaP xenografts, while 13 and 5 are unique of VCaP and C4-2B, respectively.
Thus, in contrast to the OB-BMST top 30-gene list, the Core OB-BMST is
primarily induced by VCaP cells. Most likely, this is the consequence of the more
robust OB response induced by these cells, as compared to C4-2B (Fig. 1A).
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Fig. 2. The Core OB-BMST represents the fraction putatively specific for the BM/B response to
osteoinductive PCa cells. A. Four-set Venn diagram showing the comparison of primary MCa, PCa with the
OB-BMST after subtraction of gene signatures derived from desmoplastic, wound-healing, inflammatory and
non-osteotropic cancers (5 ‘‘Curated 2’’ OB-BMST, sum of grey and red areas). The red shaded area is
referred to as ‘‘Core OB-BMST’’ (complete list reported in S2 Table), genes of the grey area represent a
potential osteotropic signature (complete list reported in S6 Table). B. Top 30 up-regulated genes of the Core
OB-BMST derived from C4-2B (black bars) and VCaP (grey bars) xenografted bones.
doi:10.1371/journal.pone.0114530.g002
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Angiogenesis and osteogenesis are the key processes
represented in the OB-BMST and Core OB-BMST
GO terms analysis shows that up-regulated genes in both the OB-BMST and Core
OB-BMST common to VCaP and C4-2B (‘‘common’’ OB-BMST/Core OB-
BMST) are highly associated (FDR,0.05) with annotations terms related to
angiogenesis, skeletal system development and enzyme-linked receptor protein
signaling pathway (Fig. 3 A and B). ECM organization and cell adhesion are also
highly represented in the OB-BMST, while TGFb receptor signaling appears as
additional term in the Core OB-BMST. Down-regulated genes are mainly grouped
in GO terms related to cell cycle (Fig. 3A and B). Most likely, the complete lack of
hematopoiesis in the BM spaces invaded by cancer cells (myelophthisis) is
responsible for this phenomenon.
The protein network analysis reveals fibronectin 1 (Fn1) as the central node of
the OB-BMST, with 31 interaction partners involved in ECM remodeling (e.g.
Bgn, Fbln1, Fmod, Adamts4, Timp1, Postn, Mmp14), skeletal system develop-
ment (Sparc, Col1a1, Mmp13, Serpinh1), Wnt signaling (Sdc1, Ryk, Jup), cell
adhesion (Mcam, Thbs2, Itgb5), angiogenesis (Jun, Nos3), wound healing (Gfap,
Lox) and epithelial-to-mesenchymal transition (Tgfb3, Snai1). A second
prominent network consists of 10 collagen family members and is linked to Fn1
by Sdc1 and 2 (Fig. 3C). Analysis of protein interaction networks in the Core OB-
BMST points at Tgfb receptor and Ephrin signaling (Fig. 3D).
Among the 67 activated upstream regulators identified for the ‘‘common’’ OB-
BMST, 15 represent growth factors (Tgfb1, Ctgf, Fgf2, Agt, Igf, Gdf2, Vegfa,
Bmp2, Tgfb3, Bmp4, Igf1, Jag1, Lep, Pdgfb, Inhba) and 6 represent cytokines (Prl,
Idn1, Il17a, Csf1, Osm, Wnt1) (S3 Table). For the ‘‘common’’ Core OB-BMST,
the number of activated biological upstream regulators is considerably restricted
(Tgfb1, Ephb4, Kdm5b, Nupr1, Igfr1 and Fgf2). Only Tgfb1 and Fgf2 are retained
from the OB-BMST, and Ephb4 emerges as an activator of the canonical Tgfb
pathway (Table 1). Tgfb1 has the highest activation score, stringency and largest
number of predicted target molecules for both transcriptomes (Table 1 and S3
Table).
The analysis of over-represented sequence motifs in the promoters of the genes
of the Core OB-BMST shows that only the up-regulated genes have significant
motif over-representation, namely for Foxo4, Meis1 and Maz (Table 2). The
processes associated with the Foxo4-, Meis1- and Maz-linked genes are
angiogenesis and vasculogenesis (P510E-09), cell junction assembly and
organization (P510E-05) and collagen fibril organization and extracellular matrix
organization (P510E-03).
Collectively, the findings above strongly suggest angiogenesis and osteogenesis
as major biological processes and Tgfb as the major signaling pathway involved in
osteoblastic bone metastasis.
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The OB-BMST and Core OB-BMST partially overlap with ‘‘stem
cell niche’’ signatures
The literature survey for 96 of the most up-regulated genes of the Core OB-BMST
shows that 32 genes (33.3%) are involved in OB recruitment/function, 6 genes
(6.3%) in OC recruitment/function, 34 genes (35.4%) in EC recruitment/function
and 13 genes (13.5%) in MSC differentiation/function. Notably, 10 genes (10.4%)
are documented HSC niche components and 9 genes (9.4%) cancer cell niche
components. It has to be considered that single genes could be assigned to more
than one category. Forty-one genes (42.7%) are unrelated to any of the categories
above (Table 3, S4 Table).
To further corroborate the contribution of SC niche-related genes to the
osteoblastic response, we compared both the OB-BMST and the Core OB-BMST
with two SC niche signatures publicly available for the HSC [13] and for the
developing prostate (uro-genital mesenchyme, UGM) [14]. The OB-BMST
contains 14 genes (45%) of the 31 HSC-gene signature [13] and 208 genes
(14.8%) of the 1405 UGM-gene signature (Fig. 4A and B). As an effect of the
curation, 5 (16%) of the HSC genes and 141 (11%) of UGM genes are retained in
the Core OB-BMST (Fig.4C and D, Table 4 and S5 Table). Importantly, 37%
and 42% of the up-regulated genes of OB-BMST and Core OB-BMST,
respectively, represent genes up-regulated also in the UGM signature.
The Core OB-BMST SC niche gene Epha3 is specific for the BM/B
stroma reaction in osteoblastic bone metastasis
The up-regulation of 4 representative SC niche genes, namely pleiotrophin (Ptn),
Eph receptor a3 (Epha3), Cd109 and Slit homolog 3 (Slit3) in VCaP and C4-2B
bone xenografts is confirmed by RT-qPCR analysis (Fig. 4E). Slit3 and, to a minor
extent, Cd109, are significantly up-regulated also in the stroma of orthothopic
VCaP (Fig. 4F). Ptn and, Cd109 are significantly up-regulated also in the stroma
of subcutaneous C4-2B xenografts (Fig. 4G). In contrast, none of the 4 SC niche
genes are significantly induced in the stroma of subcutaneous VCaP xenografts
(Fig. 4G). A significant induction of these genes is also shown in the stroma of
bone xenografts of the pro-osteolytic PC-3 cells (Fig. 4H), yet this is negligible
when compared to the induction in the stroma of bones xenografted with
osteoinductive C4-2B and VCaP cells. These results indicate that, at least in cancer
cell xenografts, induction of Epha3 expression is the most specific for the
osteoblastic response.
Fig. 3. Enriched GO terms and protein interaction networks within the ‘‘common’’ OBMST and Core OB-BMST. GO terms enriched in the ‘‘common’’
OB-BMST (FDR#5.50E-03) (A) and in the ‘‘common’’ Core OB-BMST (FDR#5.0E-01) (B). Protein interaction networks by STRING analysis in the
‘‘common’’ OB-BMST (C) and in the ‘‘common’’ Core OB-BMST (D). The thickness of lines correlates positively with the confidence score that was obtained
for each protein interaction. Abbreviation: FDR, false discovery rate.
doi:10.1371/journal.pone.0114530.g003
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Expression of the Core OB-BMST proteins PTN, EPHA3 and
FSCN1 is restricted to human PCa bone metastasis
In order to verify the translational value of Core OB-BMST genes, we investigated
the protein expression of the two SC-niche components PTN and EPHA3, and of
the most up-regulated gene FSCN1 in normal prostate and bone, and in primary
and bone metastatic PCa.
Normal bone and hematopoietic marrow (Fig. 5A) are devoid of PTN
immunoreactivity. In bone metastases (Fig. 5D), OBs and newly embedded
osteocytes are PTN-positive, but only in areas of cancer cell infiltration. Cancer
cells are mostly negative, with the exception of few cells in proximity of bone
forming OBs. In normal prostate (Fig. 5G) isolated clusters of luminal cells of
some acini are PTN-positive, whereas the majority of acini are devoid of PTN
immunoreactivity. Sections of PCa (Fig. 5J) are mostly negative, with the
exception of few cancer cells in areas of high Gleason grade (not shown).
Strongly EPHA3-immunoreactive stellate-like cells are found scattered within
normal BM (Fig. 5B) and, with increased density, in the tumor stroma of bone
metastases (Fig. 5E). OBs, osteocytes and OCs are negative, as well as the majority
of cancer cells. In normal prostate approximately half of the acini are EPHA3
negative, whereas in the other half discrete portions of the basal layer are positive
(Fig. 5H). Positive staining is also found in rare myofibroblasts. In contrast, in
primary PCa, cancer cells of all neoplastic acini are invariably EPHA3 negative,
with no modification of the staining pattern in the stroma compartment
(Fig. 5K).
Table 1. Activated upstream regulators of the ‘‘common’’ Core OB-BMST.
Gene
Symbol Gene Name
Fold
Change
Molecule
Type
Activation z-
score
p-value of
overlap Target molecules in dataset
Tgfb1 transforming growth
factor, beta 1
growth
factor
3.47 3.54E-12 Abca1,Anpep,Arf4,Bmp1, Cav2,Cdc,Cnn3,Col16a1,
Ece1,Elk3,Fermt2,
Fscn1,Gfap,Gns,Hes1,Hexb,Hey1,Jup,Ltbp3,Mboat2,
Mphosph9,Mybl2,Myof,Nab2,Nos3,Nupr1,Olr1,Pdlim4,
Plat,Plk2,Plod1,Plscr1,Pold1,Prim1,Rad51ap1,Ramp2,
Serpine2,Ski,Slc39a1,
Smad6,Snai1,Tgfbr1,Tgfbr2,Tyms,Zwint
Ephb4 EPH receptor B4 3.1 kinase 2.00 9.51E-04 Smad6,Tek,Tgfbr1,Tgfbr2
Kdm5b lysine (K)-specific
demethylase 5B
transcrip-
tion regu-
lator
2.00 2.03E-02 Hmmr,Ncaph,Recql,Smc5
Nupr1 nuclear protein, tran-
scriptional regulator,
1
6.97 transcrip-
tion regu-
lator
2.12 3.44E-02 B3gnt5,Brcc3,Gch1,Gk, Gtse1,Mms22l,Nupr1,Spag5,Stil
Igf1r insulin-like growth
factor 1 receptor
transmem-
brane
receptor
2.00 3.70E-02 Nos3,Plat,Prkcdbp,Snai1, Tyms
Fgf2 fibroblast growth fac-
tor 2 (basic)
growth
factor
2.35 8.39E-02 Anpep,Efnb2,Gfap,Nos3, Plat,Snai1
doi:10.1371/journal.pone.0114530.t001
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In normal bone stellate cells within the hematopoietic marrow are strongly
FSCN1-positive (Fig. 5C), but OBs, lining cells, osteocytes and OCs are FSCN1-
negative. In contrast, in PCa bone metastasis (Fig. 5F), active OBs, osteocytes and
fibroblast-like stromal cells surrounding areas of cancer cell growth are FSCN1-
positive, while cancer cells are negative. In normal prostate, (Fig. 5I) FSCN1
immunoreactivity is detected in ECs of small vessels and in scattered, fibroblast-
like cells. In PCa (Fig. 5L) the expression pattern of FSCN1 is similar to normal
prostate tissue.
These findings further support the translational value of the OB-BMST and
demonstrate that the Core OB-BMST contains genes that are specifically induced
in the stroma of bone metastatic, but not of primary PCa.
The OB-BMST also contains gene signatures not unique to
osteoblastic bone metastasis
As outlined above, the curation strategy has led to the definition of 3 additional
components within the OB-BMST.
One component, covering 8.7% of the OB-BMST genes, matches with
previously generated, inflammatory, wound healing and desmoplastic response
signatures [15–19] (S6 Table).
Another component covers 8.8% of the OB-BMST and shares genes with
signatures previously retrieved from non-osteotropic cancers such as gastric [20],
pancreatic [21, 22], colorectal [23] and esophageal [24, 25] (S6 Table).
The last component covers 9.9% of the OB-BMST and shares 88 genes with
signatures obtained from primary MCa [12, 26–29] and PCa [29–33], known for
their high propensity to metastasize to bone (osteotropism) [4, 5] (Fig. 2A and S6
Table). This component may represent a signature predicting disease progression
as bone metastasis. Unfortunately, this possibility could not be validated in PCa
since no gene expression datasets for metastatic outcome of primary PCa are
publically available.
Table 2. Promoter sequence motifs overexpressed in the common Core OB-BMST.
Transcription factor Genes Enrichment factor p-value Biological processes
V$MAZ_Q6 NAB2, ELK3, HES1, S100A16, PRKCDBP,
RAMP2, STC1, BMP1, ITM2C, MRC2,
FKBP10, ABCA1, ARF4, JUP, SLCO2A1,
SLC39A13, PLAT, CNN3, PHLDB1,
CD109, ANXA6
1.4 1.36E-06 Collagen fibril organization and
extracellular matrix organization
(10E-03)
V$MEIS1_01 SLC30A4, ELK3, COPZ2, RAMP2,
BMP1, PTN, PDLIM4, EPHA3, JUP,
HOXA3, PHLDB1, SNAI1
1.3 3.20E-05 Cell junction assembly and organi-
zation (10E-05)
V$FOXO4_01 COLEC12, TEK, APC, NOS3, STC1, GNS,
PTN, PDLIM4, MRC2, SMAD6, PITX1,
EMCN, JUP, HOXA3, HEY1, CAV2, RAMP3
1.3 5.61E-05 Angiogenesis and vasculogenesis
(10E-09 and 10E-10)
doi:10.1371/journal.pone.0114530.t002
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Table 3. Literature survey of up-regulated Core OB-BMST genes.
Gene symbol Gene name
Fold change VCaP/
C4-2B FDR VCaP/C4-2B Functions References
Hematopoietic stem cell niche components
Abca1 ATP-binding cas-
sette, sub-family A
(ABC1), member 1
3.32/4.05 6.73E-06/4.65E-06 Regulation of HSC niche Westerterp et al., 2012
Cdh2 Cadherin 2 5.94/1.86 1.68E-05/1.81E-02 Mediates homophilic adhesion to
osteoblasts in the HSC niche
Zhang et al., 2003; Arai et
al., 2102
Epha3 Eph receptor A3 17.53/14.39 1.20E-06/1.51E-06 Homing factor for stem cells to
the BM
Ting et al., 2010
Lamb1 Laminin B1
subunit 1
4.38/5.72 2.21E-05/3.93E-06 Laminins facilitate survival and self-
renewal of pluripotent stem cells
Gu et al, 2003; Rodin et
al., 2010
Nos3 Nitric oxide
synthase 3,
(endothelial cell)
3.12/3.22 6.73E-06/2.77E-06 Regulates maintenance and
mobilization of stem cells in
the BM
Aicher et al., 2003; North
et al., 2009
Olfml3 Olfactomedin-like 3 5.44/3.37 1.20E-06/5.90E-06 Regulates assembly of HSC
perivascular niche
Miljkovic-Licina et al.,
2012
Ptn Pleiotrophin 8.55/16.02 1.20E-06/3.08E-07 Regulates the maintenance of
the HSC pool; homing factor
for stem cells to the BM
Himburg et al., 2012
S1pr1 Sphingosine-1
phosphate
receptor 1
4.05/3.77 1.96E-06/1.75E-06 Expressed on HSCs; S1P
(5ligand) facilitates the egress of
committed hematopoietic progenitors
from the BM into the blood
Juarez et al., 2012
Sstr2 Somatostatin
receptor 2
8.70/1.98 1.59E-07/1.45E-04 Expressed on HSCs, involved
in BM homing
Oomen et al., 2002
Tek Endothelial-specific
receptor tyrosine
kinase
3.48/4.57 6.73E-06/1.10E-06 Expressed in HSCs; maintains
quiescent status of HSCs
Yano et al., 1997; Martin
et al., 2008
Cancer cell niche components
Bmp1 Bone morphoge-
netic protein 1
9.11/4.29 1.34E-06/3.84E-06 Promotes proteolytic activation of
lysyl oxidase
Maruhashi et al., 2010;
Erler et al., 2009
Epha3 Eph receptor A3 17.53/14.39 1.20E-06/1.51E-06 Promotes angiogenesis, expressed
on tumor-initiating cell population,
maintains tumor cells in a less
differentiated state
Xi et al., 2012; Day et al.,
2013
Ephb4 Eph receptor B4 3.10/3.37 1.17E-05/3.84E-06 Deregulated Ephb4-ephrinb2 signal-
ing may contribute to the acquisition
of a metastatic phenotype; modu-
lates angio-/lymph-angiogenesis
Kaenel et al., 2011;
Abe´ngozar et al., 2012
Lamb1 Laminin B1,
subunit 1
4.38/5.72 2.21E-05/3.93E-06 Displays anti-adhesive functions
and has potential implications for
cell migration during matrix
remodeling; angiogenesis
Santos-Valle et al., 2012;
Patarroyo et al., 2002;
Ghajar et al., 2013
Ltbp4 Latent transforming
growth factor beta
binding protein 4
3.37/7.37 6.73E-06/3.08E-07 Modulates activation of
latent TGFb
Ghajar et al., 2013
Nid1 Nidogen 1 -/5.98 -/2.74E-06 Overexpressed in BM-like
microvascular niche in vitro
Ghajar et al., 2013
Olfml3 Olfactomedin-like 3 5.44/3.37 1.20E-06/5.90E-06 Promotes angiogenesis and
tumor growth
Miljkovic-Licina et al.,
2012
Ptn Pleiotrophin 8.55/16.02 1.20E-06/3.08E-07 Stimulates angiogenesis; activates
CAFs; stimulates cancer cell
growth
Perez-Pinera et al., 2007;
Diamantopoulou et al.,
2012
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Discussion
This is the first comprehensive transcriptome analysis defining the BM/B stroma
reaction in xenograft models PCa-induced osteoblastic bone metastasis. The
stroma specificity of this transcriptome, designated as OB-BMST, has been
provided by the TCTP [11], a method allowing the analytical dissection of tumor
stroma and cancer cell transcriptomes in situ, without physical separation of the
two compartments.
Osteogenesis and angiogenesis are the key processes in the OB-
BMST and Core OB-BMST
The GO terms, the principal upstream regulators and the major effector cells of
the OB-BMST and Core OB-BMST strongly indicate that osteogenesis and
angiogenesis are the predominant processes in the BM/B stroma reaction of PCa-
induced, osteoblastic bone metastasis. The scarcity of genes related to OCs
(4 genes encoding inhibitors of OC recruitment/activity and only two genes
promoting OC recruitment) in the Core OB-BMST and the lack of genes
encoding master factors stimulating OC recruitment (Rankl, Csf-1 and IL-8) in
the OB-BMST further support the notion that, in osteoblastic bone metastases,
there is no increase in OC recruitment [34].
Osteogenesis
The contribution of osteogenesis to the OB-BMST/Core OB-BMST could be
anticipated and confirms the robustness of the two mouse models of osteoblastic
bone metastasis adopted in this study.
Markers and/or effectors of MSC and OB recruitment and function are highly
enriched in the Core OB-BMST, where they represent 40% of the 96 most up-
regulated genes. This indicates that the Core OB-BMST better illustrates the bone
context-specific, stromal response to osteoinductive cancer cells than the original
OB-BMST. Furthermore, the finding that the osteogenesis-related genes among
the top 30 Core OB-BMST genes are predominantly induced by VCaP cells seems
to underscore the higher osteoinductive potential of these cells, as compared to
C4-2B.
Cancer-associated fibroblasts (CAFs) are an additional cell population
contributing to the OB-BMST as indicated by: a) the association with a previously
Table 3. Cont.
Gene symbol Gene name
Fold change VCaP/
C4-2B FDR VCaP/C4-2B Functions References
S1pr1 Sphingosine-1
phosphate
receptor 1
4.05/3.77 1.96E-06/1.75E-06 Regulates pre-metastatic
niche; angiogenesis
Deng et al., 2012; Yang et
al., 2013
Note: 96 genes corresponding to all genes more than 3 fold induced in both xenografts and the top 30 of VCaP and C4-2B xenografts were reviewed.
Complete references can be found in S4 Table.
Abbreviations: BM, bone marrow; CAF, cancer-associated fibroblast; FDR, false discovery rate; HSC, hematopoietic stem cell.
doi:10.1371/journal.pone.0114530.t003
Gene Signature of the Stroma Response in Osteoblastic Bone Metastasis
PLOS ONE | DOI:10.1371/journal.pone.0114530 December 8, 2014 14 / 32
Gene Signature of the Stroma Response in Osteoblastic Bone Metastasis
PLOS ONE | DOI:10.1371/journal.pone.0114530 December 8, 2014 15 / 32
retrieved myofibroblasts/fibroblasts gene signature [12], b) the enrichment of CAF
markers (i.e., Pdgfrb and Sparc) and recruiting factors (Tgfb1, Tgfb3, Fgf2 and
Pdgfbb) [35], c) the pivotal position of CAF-derived ECM proteins (Fn1 and
collagens) [36] in the protein network and d) the expression of ASPN and POSTN
by myofibroblasts in primary and bone metastatic PCa. This finding is in
agreement with a previous study reporting that a CAF signature is overrepresented
in bone metastases, as compared to lung, liver and brain metastases [37].
CAFs and OBs share a common cell-of-origin (MSC/pericyte) and some degree
of marker expression, and their recruitment is induced by identical growth
factors. Therefore, it is tempting to speculate that OBs are an additional, bone-
specific population of CAFs and that the osteoblastic response is a tissue-specific
manifestation of desmoplastic response to cancer cell invasion.
Fscn1, one of the 7-gene set, is the top up-regulated gene of the Core OB-
BMST. Its encoded protein is critical for cell-matrix adhesion, cell interactions
and cell motility. In normal adult tissue, it is expressed exclusively by dendritic
cells [38]. In solid cancers, FSCN1 has been mainly associated with cancer cells
Table 4. Core OB-BMST genes overlapping with the hematopoietic and developing prostate stem cell niche signatures.
Hematopoietic stem cell niche
Hes1 Ptn Slc8a1 Slco2a1 Tspan6
Developing prostate stem cell niche
Antxr2 Anxa5 Anxa6 Apbb1 Aplnr Aplp1 Arhgef25 B3gnt9-ps B4galt2 Bicc1 Casp12
Ccdc80 Cd200 Cd40 Cd93 Cdh15 Cdh2 Cdo1 Cdr2l Cgref1 Chst2 Cnn3
Col16a1 Copz2 Cplx1 Creb3l1 Cspg4 Cxx1a Cxx1b Cygb Cyp7b1 Ddr2 Dnm1
Ednrb Egfl7 Eln Emcn Eng Enpep Epb4.1l2 Epha3 Fabp7 Fam181b Fcgrt
Fermt2 Fgfr1 Fibin Fkbp10 Fkbp7 Fkbp9 Foxc2 Gas1 Gdf10 Gimap6 Gja4
Gli1 Gli2 Hey1 Hip1 Il6st Itm2a Jam2 Kdelr3 Ldb2 Lepre1 Leprel2
Lifr LOC100862618 Lpar1 Mageh1 Matn2 Mrc2 Msc Ndrg4 Nid1 Nos3 Npdc1
Ntn1 Olfml3 Pcdhga1 Pcdhga2 Pcdhga3 Pcdhga4 Pcdhga5 Pcdhga6 Pcdhga7 Pcdhga8 Pcdhga9
Pcdhga10 Pcdhga11 Pcdhga12 Pcdhgb1 Pcdhgb2 Pcdhgb4 Pcdhgb5 Pcdhgb6 Pcdhgb7 Pcdhgb8 Pcdhgc3
Pcdhgc4 Pcdhgc5 Phldb1 Phldb2 Pitx1 Pkd2 Plat Plod1 Plvap Pou3f1 Prkcdbp
Ptn Ptprz1 Rab13 Ramp2 Rapgef4 Rerg Rftn2 Rhoj Sdc3 Sec16b Selm
Slc22a17 Slc2a10 Slc8a1 Slc9a3r2 Slit3 Snai1 Sox18 Spred1 Sspn St6galnac4 Stmn3
Tbx2 Tek Tgfbr2 Tmem119 Tmem45a Tspan4 Ttyh2 Vasn Wwtr1
Note: Genes in bold are present in both stem cell niche signatures.
doi:10.1371/journal.pone.0114530.t004
Fig. 4. The OB-BMST and Core OB-BMST contain genes from stem cell niche signatures. Venn diagrams showing the number of overlapping OB-
BMST (A and B) and Core OB-BMST (C and D) genes with gene signatures derived from the hematopoietic (A and C) and the developing prostate (B and
D) stem cell niches. Relative expression levels of Ptn, Epha3, Cd109 and Slit3. E. VCaP (grey, n53) and C4-2B (black, n54) intra-osseous xenografts;
values are shown as fold change (mean ¡ SD) relative to contralateral and sham-operated bones. F. VCaP (grey, n55) orthotopic xenografts; values are
shown as fold change (mean¡ SD) relative to intact and sham-operated prostate. G. VCaP (grey, n53) and C4-2B (black, n55) subcutaneous xenografts;
values are shown as fold change (mean¡ SD) relative to intact skin. H. PC-3 (light grey, n56) intra-osseous xenografts; values are shown as fold change
(mean ¡ SD) relative to contralateral and sham-operated bones (n53–4). *, P,0.01; **, P,0.001; ***, P,0.0001; ****, P,0.0001. Abbreviations: HSCs,
hematopoietic stem cells; UGM urogenital mesenchyme; Ptn, pleiotrophin; Epha3, Eph receptor a3; Slit3, slit homolog 3.
doi:10.1371/journal.pone.0114530.g004
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and its stromal expression has been generally overlooked [39]. Here we show for
the first time that, in bone metastasis, the expression of this protein is induced de
novo in OBs and osteocytes, and in CAFs. This finding suggests FSCN1 as a
candidate biomarker for osteoblastic bone metastasis.
Angiogenesis
The contribution of angiogenesis to the stroma response in osteoblastic bone
metastasis is substantiated by: a) the up-regulation of markers of ECs of endosteal,
sinusoidal BM vessels, namely endomucin [40] and laminin B1 [41] and of
pericytes, namely Mcam [42] and nestin [43] in the OB-BMST, b) the prominent
representation (35%) of markers and/or effectors of EC recruitment and function
Fig. 5. PTN, EPHA3 and FSCN1 protein expression is induced in human bone metastatic, but not
primary PCa. Immunohistochemical detection of PTN (A, D, G and J), EPHA3 (B, E, H and K) and FSCN1
(C, F, I and L) in normal bone (A, B and C), in osteoblastic PCa bone metastasis (D, E and F), in normal
prostate (G, H and I) and in primary PCa (J, K and L). Insets represent a higher magnification of selected
areas. Scale bar550 mm. Abbreviations: PTN, pleiotrophin; EPHA3, Eph receptor A3; FSCN1, fascin
homolog 1.
doi:10.1371/journal.pone.0114530.g005
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among the 96 most up-regulated genes of the Core OB-BMST, c) the presence of
VEGFA and FGF2, the most important factors in EC recruitment [44], of PDGFB,
a critical recruitment factor for pericytes in normal and tumor-induced
neovasculature [45] and of CTGF, a factor coordinating angiogenesis in bone
[46], among the activated upstream regulators of the OB-BMST.
The finding that angiogenesis is a prominent process in osteoblastic bone
metastasis is not surprising considering that, in physiological bone remodeling, it
is tightly coupled to osteogenesis [40] and is required for primary and metastatic
tumor growth [44]. It is also consistent with recent studies highlighting the
relevance of sprouting BM neovasculature as a metastatic niche supporting cancer
cell growth [47]. Nevertheless, it is surprising that the role of angiogenesis in
osteoblastic bone metastasis is almost unexplored [4]. To our knowledge, only
two studies have investigated the impact of anti-angiogenic therapy in mouse
models of osteoblastic bone metastasis and shown inhibition of both osteoblastic
response and tumor burden [48, 49]. Further investigation is warranted for
determining the relevance of angiogenesis and the efficacy of anti-angiogenesis in
osteoblastic bone metastasis.
Ephb4 is an up-regulated OB-BMST gene that also emerges as one of the
upstream regulators of the Core OB-BMST. The ephrinB2/Ephb4 axis is involved
in coupling bone resorption to bone formation whereby OC-derived ephrinB2, by
binding to Ephb4 on MSCs, induces their differentiation into OBs [50]. In line
with this, interference with the ephrinB2/EphB4 axis by myeloma cells represses
bone formation [51]. This axis plays also an essential role in angiogenesis [52].
Accordingly, the ephrinB2/EphB4 axis may mediate also coupling of angiogenesis
and osteogenesis in osteoblastic bone metastases.
The OB-BMST highlights amplification of SC niche components
Osteoinductive PCa cells amplify the HSC niche
The dominant angiogenic and osteoblastic responses found in the OB-BMST/
Core OB-BMST are paralleled by up-regulation of several genes encoding proteins
controlling homing/mobilization, self-renewal, dormancy or expansion of HSC
and, therefore, to be considered as components of the HSC niche. Furthermore,
the transcriptional components predicted to be active in the Core OB-BMST
(Maz, Meis1 and Foxo4) have been implicated in both hematopoiesis [53–55] and
angiogenesis [56–58].
The endosteal (OBs) and vascular (EC/pericytes) are considered the two most
relevant HSC niches in the BM (reviewed in [59]) and both angiogenesis and
osteogenesis are required for generation of the HSC niche [60]. Very recently,
elegant studies on the spatial organization of HSC niches have revealed that the
vascular and endosteal niches constitute a single structural and functional entity
[41, 60]. Collectively, these studies indicate that physiological angiogenesis and
osteogenesis are merged spatially and temporally to build the HSC niche. Our
findings suggest that, in osteoblastic bone metastasis, the angiogenic and OB
responses are also finalized to the expansion of the HSC/metastatic niche.
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Therefore, they seem to validate a model of cancer cell-metastatic niche
interaction, whereby cancer cells not only occupy and activate, but also amplify a
pre-existing SC niche, thus fuelling further tumor growth [61].
Several molecules acting at the HSC niche interface, namely, kit-ligand (Kitlg or
stem cell factor, SCF) [62], growth-arrest specific 6 (GAS6) [63], annexin A2
(Anxa2) [64], chemokine (C-X-C motif) ligand 12 (CXCL12), N-cadherin (Cdh2)
[65, 66] and trombospondin 1 (Thbs1) [47] have been shown to function also as
components of the metastatic niche in models of osteolytic bone metastases. Only
one of these genes, namely Cdh2, is present in the Core OB-BMST gene list. Most
likely, this poor agreement reflects the fact that the HSC niche components of the
Core OB-BMST are specific for the osteoblastic bone metastasis. In line with this,
preliminary results from our laboratory show that the stroma transcriptome from
xenograft models of osteolytic bone metastases differs substantially from the OB-
OBMST and shares only 4 out of the 14 HSC genes present in the Core OB-BMST
(JH, AW and MGC, unpublished).
Among the genes encoding components of the HSC niche, Ptn and EphA3 are
especially interesting. Ptn has been reported to be secreted by OBs [67] and ECs
[68] and to be integrated in new bone matrix [67]. Here we confirm PTN
expression by active OBs, but not by the BM vasculature of human samples of
osteoblastic bone metastasis. While its effects on the OB lineage are still disputed
[67], Ptn is known to promote tumor angiogenesis, CAF recruitment and ECM
remodeling [69]. Notably, Ptn has been demonstrated to be a component of the
BM vascular niche regulating HSC self-renewal and retention in vivo [68].
Bidirectional signaling between Eph receptors and their membrane-bound
ligands, ephrins, has been shown to play a role in cell migration and adhesion, and
patterning of vascular, nervous and skeletal systems [70]. Notably, Ephs/ephrins
are expressed in adult, epithelial SC niches where they modulate SC function [71].
However, the involvement of EphA3 in these processes is still unexplored. EphA3
mRNA expression in cultured mouse OBs has been reported, but with no
indication of its function [72]. EphA3, together with EphA2 and EphA4, has been
found to be expressed by mouse BM stromal cell lines and involved in homing
and mobilization of HSCs [73]. We observed EphA3 protein expression by
stellate-like cells within normal, human BM and in the tumor stroma of human
bone metastasis, but not in bone or other BM stromal cells. This discrepancy may
be possibly due to species differences and/or in vitro versus in vivo detection.
Our results and the observations above propose PTN and EPHA3 as HSC niche
components that may also be part of the BM metastatic niche.
Osteoinductive PCa cells also induce their own niche
Remarkably, 37% and 42% of the up-regulated genes of the OB-BMST and Core
OB-BMST, respectively, are part of the developing prostate SC niche (UGM)
signature [14]. Yet, approximately 20% of these genes are also functionally linked
to the HSC niche. An example for these is Ptn, overexpressed in the Core OB-
BMST, and component of both the HSC [13], where it modulates HSC
maintenance [68], and prostate SC [14] niches, where it regulates branching
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morphogenesis [74]. Interestingly, binding sites for Maz, one the transcription
factors predicted to be active in the Core OB-BMST, have been also found
enriched in the UGM [14].
Collectively, these findings suggest that osteoinductive PCa cells not only
amplify a pre-existing, BM HSC niche, but also induce de novo an ectopic
epithelial SC niche reminiscent of the organ of origin. A similar mechanism has
been demonstrated in MCa metastasis to the lung, whereby tumor initiating cells
educate stromal cells of the target organ to express ECM components of the SC
niche of the developing mammary gland, such as POSTN, which then become
components of the metastatic niche supporting stem-like cancer cells maintenance
[75].
The combinatorial niche association of HSC and epithelial SC niches may
create a ‘‘soil’’ suitable for stem-like cancer cell growth, but hostile for HSCs, thus
explaining the hematopoietic aplasia (myelophthisis) occurring in bone metastasis
[76] and in myeloproliferative neoplasia [77]. It may also correspond to the
growth requirements specific for osteoinductive PCa cells. Furthermore, the
capacity to induce de novo prostate epithelial SC niche components in the BM, but
not in other tissues, as shown here, could also be a mechanism explaining the
osteotropism of PCa cells.
The OB-BMST also contains gene signatures not unique to
osteoblastic bone metastasis
Inflammatory/wound healing/desmoplastic response
A first fraction of the OB-BMST contains genes of inflammation/wound healing/
desmoplasia-related signatures. This is not surprising in view of the similarities
between wound healing and cancer [78] and of the persistent activation of
wound-healing and inflammatory programs in tumors [79]. Clearly, genes
contained in this fraction are not cancer-restricted, thus limiting their use as
cancer biomarkers. POSTN, one of these genes, has been proposed as a serum
biomarker for bone metastasis [80]. However, its validity in this regard should be
proven versus a clinical scenario of inflammation.
‘‘Universal’’ stroma response to cancer
A second fraction of the OB-BMST contains genes shared by cancers with no
or low propensity to metastasize to bone. This component is species, tissue
and cancer cell type independent and thus seems to be a ‘‘universal’’ stroma
response to cancer cells. Accordingly, genes part of this OB-BMST
component could represent general biomarkers of cancer, but not of a
specific cancer type.
Stroma osteomimicry in primary tumor as possible determinant of
cancer osteotropism
An additional fraction of the OB-BMST contains genes shared by primary PCa
and MCa known for their high propensity to metastasize to bone (osteotropism).
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It has been hypothesized that the osteotropism of PCa is conferred by the
capacity of PCa cells to aberrantly express OB-restricted proteins, such as
osteopontin and osteocalcin. This phenomenon, named osteomimicry, would
allow the cancer cells to thrive specifically in the bone microenvironment [81].
Recently, it has been suggested that osteomimicry by the stroma of the primary
tumor, rather than by cancer cells, may also explain the osteotropism of MCa
[37]. Our results may extend this notion to PCa and expand the list of molecules
potentially involved.
Mcam, also known as Cd146, is of special interest in this regard. It is a cell
adhesion molecule expressed at the intercellular junction of ECs and in activated
T lymphocytes. A homophilic MCAM interaction between these cells mediates
lymphocyte trafficking at inflammatory sites [82]. MCAM expression in human
BM marks specifically pericytes of the sinusoids [42], an essential cell population
of the HSC niche [43]. MCAM expression by cancer cells has been reported in
most cancer types [83]. Increased stromal expression of MCAM parallels
metastatic potential in osteotropic cancers, including PCa and MCa [84, 85].
Importantly, MCAM is present in a gene signature predicting bone metastatic
progression in MCa [86]. Therefore, MCAM-mediated homophilic interaction
between cancer and BM stromal cells may represent a possible molecular
mechanism of osteotropism.
The fraction of the OB-BMST common to the stroma response of primary PCa
and MCa may contain a gene signature that may predict, similarly to MCAM,
disease progression as bone metastasis. Therefore, it warrants to be verified in
gene expression datasets, once available, of primary PCa from patients with or
without bone metastatic relapse.
Translational significance
The OB-BMST/Core OB-BMST will serve as a reference list of physiological SC
niche components to be validated as novel components of the BM/B metastatic
niche. Besides their mechanistic significance, these molecules may represent
additional therapeutic targets allowing interference with cancer cell homing,
survival and growth in the BM/B. Indeed, it has been shown that cancer cells can
be mobilized from the HSC niche into the blood by using HSC mobilizing agents
[87]. Furthermore, anti-angiogenesis, by limiting the size of the SC/metastatic
niches, may also interfere with survival and growth of osteoinductive PCa cells in
the BM/B.
Modifications of the cancer-associated plasma proteome seem to be
predominantly derived from the tumor microenvironment [88]. Therefore, the
Core OB-BMST could also provide novel stroma-derived, serum biomarkers for
the detection of bone metastatic cancer progression.
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Materials and Methods
Ethics statement
The Ethical Committee of the Canton of Bern, Switzerland, approved the overall
study protocol and tissue collection from patients (Nr 06/03). A written informed
consent was obtained from each patient.
The Committee for Animal Experimentation and the Veterinary Authorities of
the Canton of Bern, Switzerland approved the experimental animal protocols,
anesthesia, surgical procedures and post-surgical analgesia (Permit Number: 15/
07 and 6/10). Mice were housed in individual ventilated cages in strict accordance
to the Swiss Guidelines for the Care and Use of Laboratory Animals. Autoclaved
water and sterile mouse chow were provided ad libitum. For surgical
manipulation, mice were anesthetized with a cocktail of medetomidin (1 mg/kg
body weight), midazolam (10 mg/kg) and fentanyl (0.1 mg/kg) [34]. Post-
operative analgesia with buprenorphine (0.1 mg/kg) was performed for 3 days
following surgical intervention. Animals xenografted with human cancer cells
were carefully monitored for signs of pain, distress and loss of body weight.
Development of bone lesions was followed by radiography at two weeks intervals
for VCaP and C4-2B and at weekly intervals for PC-3 cells. The size of
subcutaneous and orthotopic tumors never exceeded 200 mm3. At the experi-
mental endpoint mice were sacrificed by CO2 euthanasia.
Cell culture
The PCa cell line C4-2B [89] and the luciferase-transfected C4-2Bluc [34] were
grown in T-medium [89], and the PCa cell line VCaP (kindly donated by Dr. K.
Pienta, University of Michigan, Ann Arbor) [90] in RPMI 1640 medium
(Biochrom AG, Berlin, Germany). The PCa cell line PC-3 (ATCC CRL1435) was
grown in DMEM and the prostate epithelial cell line Ep156T (kindly donated by
Dr. V. Rotter, Department of Molecular Cell Biology, Weizmann Institute of
Science, Rehovot, Israel) [91] in modified MCDB-153 medium (WKS
Diagnostics, Frankfurt am Main, Germany). All media were supplemented with
10% fetal bovine serum (Oxoid, Pratteln, Switzerland).
Xenografts
For intra-osseous xenografts, PCa cells with low/medium (C4-2B cell line) or high
(VCaP cell line) capacity to induce an osteoblast response (osteoinductive cancer
cells), and PCa cells (PC-3 cell line) with high capacity to induce an osteoclast
reaction (pro-osteolytic cancer cells) and immortalized, non-tumorigenic human
prostate epithelial Ep156T cells were inoculated in the BM cavity of the left tibia of
male CB17 SCID mice [34]. Sham-operated animals (sham) and animals not
subjected to surgery (intact) were used as controls. Development of bone lesions
was monitored by radiography. Mice xenografted with VCaP and Ep156T cells
were sacrificed after 6 weeks, and those inoculated with C4-2B after 8 weeks. PC-3
xenografts and their Ep156T controls animals were sacrificed after 33 days. Sham
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and intact animals were sacrificed at the 3 time points above. Xenografted and
control tibiae were used either for RNA isolation or immunohistochemistry.
VCaP cells were used for orthotopic (intra-prostate) implantation, while C4-
2Bluc and VCaP cells were used for subcutaneous implantation. For both types of
xenografts, a suspension of 10E06 cells was mixed with collagen (Collagen Type I
from rat tail, BD Biosciences, Allschwil, Switzerland). Prostates implanted with
collagen pellets and dermal tissue served as control. Subcutaneous tumors were
excised after 9 weeks and orthotopic tumors after 10 weeks. For more details see
S1 File.
RNA extraction
RNA was extracted from cultured C4-2B and VCaP cells, from C4-2B, VCaP,
Ep156T and PC-3 xenografted bones, from sham-operated and intact bones, and
from sub-cutaneous and orthotopic xenografts using an RNeasy isolation kit
(Qiagen, Hombrechtikon, Switzerland). The ratio of human to mouse RNA in the
xenograft samples was determined by measuring 18S and both mouse and human
b2-microglobulin, hypoxanthine phosphoribosyltransferase 1 and actin beta
expression with RT-qPCR. The human to mouse ratio was 1:1 for C4-2B, 1:5 for
VCaP and 1:9 for PC-3 intra-osseous xenografts, 4:1 for C4-2B and VCaP
subcutaneous xenografts and 1:2 for VCaP orthotopic xenografts. RNA quality
was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, Basel,
Switzerland).
Microarray hybridization and data analysis
Labeled cRNA was prepared according to Affymetrix protocols and hybridized to
Mouse Genome 430A 2.0 arrays (Affymetrix Ltd., High Wycombe, UK). The
hybridization was performed with 30 mg cRNA for VCaP and Ep156T xenografts,
and for intact, sham bones. Double the amount of cRNA was used for the C4-2B
xenografts in order to correct for the high human RNA content in these
xenografts. Three replicates were performed for all experimental groups except
sham-operated bones and Ep156T xenografts, which were done in duplicates.
Quality control of the microarray data was performed using RReportGenerator
[92] and confirmed that all arrays used in the study were of good and consistent
quality. Raw data are available on GEO (GSE22813). We computed statistical
significance using the standard moderated t-test approach of the limma package
[93] and computed local false discovery rates (FDR) [94] to adjust statistical
significance to multiple-testing.
To reduce the impact of cross-species hybridization on gene expression signals,
we re-defined probe-sets in order to use only probes considered mouse-specific
(for a detailed description of the identification of cross-hybridising probe-sets see
S1 File. After exclusion of cross-hybridizing probe-sets, the 3 control groups were
analyzed for gene expression changes using a FDR of 0.2. Only a single gene,
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namely MMP12, was differentially expressed between intact bones and sham-
operated/Ep156T-xenografted bones.
Subsequently, differential gene expression between xenografted bones and
sham-operated bones was calculated. The different human to mouse RNA ratio
for the different samples was taken into account when selecting highly stringent
thresholds in the statistical testing. Two different FDR thresholds were selected for
VCaP (FDR#3E-05) and C4-2B (FDR#1E-05) due to different distribution of
values.
Reverse transcription quantitative PCR (RT-qPCR)
RNA was reverse transcribed with M-MLV-RT (Promega, Wallisellen,
Switzerland) and random primers (Roche Diagnostics, Rotkreuz, Switzerland) in
the presence of a RNase inhibitor (Promega). mRNA expression was measured by
RT-qPCR using ABI Prism Sequence Detection Systems (Applied Biosystems,
Rotkreuz, Switzerland). The mouse and human specific gene expression assays are
listed in the S1 File. RNA expression data were analyzed with two-tailed, unpaired
t-test using GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, USA).
Immunohistochemistry
Immunohistochemical staining was performed on deparaffinized tissue sections
with the primary antibodies listed in the S1 File. Antibodies were detected using
horseradish peroxidase-conjugated biotin-streptavidin (GE Healthcare,
Glattbrugg, Switzerland) or EnVision (Dako, Baar, Switzerland) systems. 3-
Amino-9-ethyl-carbazole (AEC, Sigma) was used as a chromogen. Sections were
counterstained with hematoxilin.
Samples of normal bone were obtained from patients with coxarthrosis. PCa
bone metastasis samples were obtained from iliac crest and femur, while MCa
bone metastasis samples were obtained from the humerus. Samples of normal
prostate tissue were obtained from cystoprostatectomy for bladder cancer.
Samples of PCa of Gleason grades 3/4 were obtained from radical prostatectomy.
Validation of the stroma specificity of the OB-BMST
We confirmed the absence of 25 accepted pan-epithelial and/or prostate epithelial
cell-specific markers in the OB-BMST. Furthermore, a literature review of 15
selected genes strongly up-regulated in the OB-BMST confirmed their stromal
origin. The differential expression and stroma specificity of 7 representative genes
was validated by RT-qPCR using mouse-specific probes. We also confirmed the
stromal expression of two proteins (Aspn and Postn) encoded by up-regulated
genes of the OB-BMST. More details concerning the stroma specificity of the OB-
BMST are available in the S1 File.
Taken together these results show the reliability of our approach to analyze
specifically the stroma compartment.
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Curation strategy
To obtain a bone-specific stroma response signature we adopted the following
curation strategy (Fig. 1A). First, we subtracted from the OB-BMST desmoplastic
[15], wound healing [95] and inflammatory [16, 18, 19] response signatures.
Subtraction of the 85 overlapping genes generated a ‘‘Curated 1’’ OB-BMST list.
Next, we subtracted stroma signatures derived from cancers that do not or rarely
metastasize to bone, namely gastric [20], pancreatic [21, 22], colorectal [23] and
esophageal [24, 25] cancers. Subtraction of the 79 overlapping genes generated a
‘‘Curated 2’’ OB-BMST. From this we further subtracted stroma gene expression
signatures derived from primary PCa [29–33] and MCa [12, 26–29]. After
subtraction of the 88 overlapping genes, we obtained the Core OB-BMST, which
represents the specific BM/B response to osteoinductive PCa cells. A more detailed
description of the curation strategy is available in the S1 File.
Identification of key biological processes
The OB-BMST and Core OB-BMST common to VCaP and C4-2B (‘‘common’’
OB-BMST/Core OB-BMST) were analyzed for enriched gene ontology (GO)
terms (DAVID 6.7; FDR,0.5) and functional protein networks (STRING, 9.05;
confidence score50.4). The interaction partners highlighted by the STRING
analysis were assigned to biological processes according to BioGPS platform
(http://biogps.org/).
The upstream regulators of the ‘‘common’’ OB-BMST and Core OB-BMST
were predicted by using default options of the Ingenuity Pathway Analysis
software.
Genes of the ‘‘common’’ Core OB-BMST were analyzed for the over-
representation of sequence motifs in their promoters within 2-kilobases of the
transcription start site. Enrichment was calculated against a matched number of
randomly selected genes and represented as p values versus this random set and
also as an enrichment factor, which is the frequency of the transcription factor
binding motif within the gene cluster versus its frequency within the background
gene set as previously reported [14]. We report transcription factor motif using
enrichment factors of 1.2–1.5 and p values ,10E-05. The motif database used for
this analysis is supplied by TRANSFAC [96]. Results were further validated using
the accessible web-based tool called GeneCodis (http://genecodis.cnb.csic.es/)
[97].
Supporting Information
S1 Figure. The OB-BMST overlaps with myoepithelial/myofibroblast signature
and, to a lesser extent, with fibroblast and endothelial cell signatures. Venn
diagrams and tables showing overlap of the up-regulated genes of the OB-BMST
(human orthologs) with gene signatures previously derived from specific stromal
cell populations from normal mammary tissue, in situ (ductal carcinoma in situ,
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DCIS) and invasive MCa (Allinen et al. 2004). A. Myoepithelial/myofibroblasts. B.
Fibroblasts. C. Endothelial cells. D. Leukocytes.
doi:10.1371/journal.pone.0114530.s001 (TIF)
S2 Figure. A fraction of the OB-BMST is not specific for the BM/B response to
osteoinductive PCa cells. Relative expression levels of Postn, Aspn, Sparcl1,
Mcam, Pdgfrb, Fscn1 and Pmepa1 mRNA in intra-osseous, orthotopic and ectopic
xenografts. A. VCaP intra-osseous xenografts (grey, n53) and corresponding
sham-operated bones (white, n53) and C4-2B xenografts (black, n54) and
corresponding sham-operated bones (white, n53). Values are shown as fold-
change (mean ¡ SD) relative to contralateral bones. B. VCaP orthotopic
xenografts (grey, n55) and sham (white, n54). Values are shown as fold-change
(mean¡ SD) relative to intact prostate. C. VCaP (grey, n53) and C4-2B (black,
n55) subcutaneous xenografts. Values are shown as fold-change (mean ¡ SD)
relative to intact skin. D. PC-3 intra-osseous xenografts (light grey, n56) and
sham (white, n54). Values are shown as fold-change (mean ¡ SD) relative to
contralateral bones (n53–4). *, P,0.01; **, P,0.001; ***, P,0.0001; ****,
P,0.0001, ns 5 not statistically significant. Abbreviations: Postn, periostin; Aspn,
asporin; Sparcl1, SPARC-like 1; Mcam, melanoma cell adhesion molecule; Pdgfrb,
platelet derived growth factor receptor beta; Fscn1, fascin homolog 1; Pmepa1,
prostate transmembrane protein, androgen induced 1.
doi:10.1371/journal.pone.0114530.s002 (TIF)
S3 Figure. Periostin and asporin expression is induced in the stroma of human
bone metastatic PCa and MCa and of primary PCa. Immunohistochemical
detection of POSTN (A, C, E, G and I) and ASPN (B, D, F, H and J) in normal
bone (A and B), in PCa bone metastasis (C and D), in MCa bone metastasis (E
and F), in normal prostate (G and H) and in primary PCa (I and J). Normal bone
and hematopoietic marrow (A) are lacking POSTN immunoreactivity. In
contrast, in PCa (C) and MCa (E) bone metastases, myofibroblasts surrounding
areas of cancer cell growth are POSTN-positive. OBs, osteocytes, OCs and cancer
cells are negative. Normal prostate (G) is devoid of POSTN immunoreactivity
both in the stroma and epithelial compartment. In contrast, in PCa (I) strong
POSTN immunoreactivity is found in myofibroblasts over the entire tumor
stroma, while cancer cells are negative. The myofibroblast identity of the POSTN-
immunoreactive cells was confirmed in PCa by co-staining with a-smooth muscle
actin (not shown). In normal bone (B), ASPN immunoreactivity is detected in
OBs at sites of active bone formation, while lining cells, osteocytes and OCs are
negative. Spindle-like cells within the hematopoietic marrow are also positive. In
PCa (D) and MCa (F) bone metastases, strong ASPN immunoreactivity is
detected in active OBs, and additionally in lining cells, osteocytes, and OB
precursors. Stromal cells within areas of cancer cells are also ASPN-positive
whereas cancer cells are ASPN-negative. In normal prostate (H) ASPN
immunoreactivity is found in fibroblast-like cells and EC of small vessels, but not
in epithelial cells. In the prostate, ASPN expression is also detected in cells,
identified, in sequential sections, as neuroendocrine by expression of chromo-
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granin-A and synaptophysin and in Schwann cells (not shown). In PCa (J) the
number of ASPN-positive, fibroblast-like cells is increased. In some specimens
rare PCa cells are stained for ASPN (not shown). Insets represent a higher
magnification of selected areas. Scale bar550 mm. Abbreviations: POSTN,
periostin; ASPN, asporin.
doi:10.1371/journal.pone.0114530.s003 (TIF)
S1 Table. Differentially expressed genes of the OB-BMST: (A) C4-2B xenografts
(FDR#1E-05), (B) VCaP xenografts (FDR#3E-05) and (C) common to both
C4-2B and VCaP.
doi:10.1371/journal.pone.0114530.s004 (XLS)
S2 Table. Differentially expressed genes of the Core OB-BMST: (A) C4-2B
xenografts (FDR#1E-05), (B) VCaP xenografts (FDR#3E-05) and (C) common
to both C4-2B and VCaP.
doi:10.1371/journal.pone.0114530.s005 (XLS)
S3 Table. Activated upstream regulators of the common OB-BMST.
doi:10.1371/journal.pone.0114530.s006 (XLS)
S4 Table. Literature survey of up-regulated Core OB-BMST genes.
doi:10.1371/journal.pone.0114530.s007 (DOC)
S5 Table. Gene list of HSC niche (Charbord et al.) and prostate SC niche (Blum
et al.).
doi:10.1371/journal.pone.0114530.s008 (XLSX)
S6 Table. Overlapping genes of the OB-BMST with wound, desmoplastic
response, non-osteotropic and osteotropic gene lists.
doi:10.1371/journal.pone.0114530.s009 (XLS)
S1 File. This file contains an extended version of the Material and Methods,
including references, one Figure and 11 Tables.
doi:10.1371/journal.pone.0114530.s010 (ZIP)
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